Necrotising fasciitis (NF) due to group A β-haemolytic streptococci (GAS) is a rare but still life-threatening soft-tissue infection characterised by rapidly spreading inflammation and subsequent necrosis of the muscle fascia and of the surrounding tissues. Previous studies have emphasised that the outcome of patients with NF depends essentially on early diagnosis and treatment, consisting of extensive surgical debridement, along with appropriate antibiotic therapy. However, one of the striking features of the published series of GAS NF is that there was a delay in diagnosis in several cases, which underscores the difficulty of the early diagnosis of the condition. The goal of this article was to review the clinical features and diagnostic tools that could facilitate the early recognition of GAS NF.

Keywords:
C-reactive protein, Creatine kinase, Group A β-haemolytic streptococci, Magnetic resonance imaging, Necrotising fasciitis
1.
Dahl PR, Perniciaro C, Holmkvist KA, O’Connor MI, Gibson LE: Fulminant group A streptococcal necrotizing fasciitis: Clinical and pathologic findings in 7 patients. J Am Acad Dermatol 2002;47:489–492.
2.
Kaul R, McGeer A, Low DE, Green K, Schwartz B, Simor AE: Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997;103:18–24.
3.
Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E: Severe group A streptococcal infections associated with a toxic-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1–7.
4.
Simonart T, Simonart JM, Schoutens Ch, De Dobbeleer G, Ledoux M: Epidémiologie et étiopathogénie des fasciites nécrosantes et du syndrome de choc streptococcique. Ann Dermatol Vénéréol 1993;120:469–472.
5.
Wolf JE, Rabinowitz LG: Streptococcal toxic shock-like syndrome. Arch Dermatol 1995;131:73–77.
6.
Stamenkovic I, Lew PD: Early recognition of potentially fatal necrotizing fasciitis: The use of frozen-section biopsy. N Engl J Med 1984;310:1689–1693.
7.
Chelsom J, Halstensen A, Haga T, Hoiby EA: Necrotizing fasciitis due to group A streptococci in western Norway: Incidence and clinical features. Lancet 1994;344:1111–1115.
8.
Société Française de Dermatologie: Erysipèle et fasciite nécrosante: prise en charge. Ann Dermatol Vénéréol 2001;28:463–482.
9.
Simonart T, Simonart JM, Derdelinckx I, De Dobbeleer G, Verleysen A, Verraes S, de Maubeuge J, Van Vooren JP, Naeyaert JM, de la Brassine M, Peetermans WE, Heenen M: Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis 2001;32:E9–E12.
10.
McGregor RR: Alcohol and immune defense. JAMA 1986;256:1474–1479.
11.
Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE: A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999;103:783–790.
12.
Kakis A, Gibbs L, Eguia J, Kimura J, Vogelei D, Troup N, Stevens D, Kaplan EL, Johnson DR, Conte JE Jr: An outbreak of group A streptococcal infection among health care workers. Clin Infect Dis 2002;35:1353–1359.
13.
Bisno AL, Stevens DL: Streptococcal infection of skin and soft tissues. N Engl J Med 1996;334:240–245.
14.
Aitken DR, Mackett T, Smith LL: The changing pattern of hemolytic streptococcal gangrene. Arch Surg 1982;117:561–567.
15.
Saiag P, Le Breton C, Pavlovic M, Fouchard N, Delzant G, Bigot JM: Magnetic resonance imaging in adults presenting with severe acute infectious cellulits. Arch Dermatol 1994;130:1150–1558.
16.
Bernard P: Dermo-hypodermal bacterial infections: Current concepts. Eur J Med 1992;1:97–104.
17.
Umbert IJ, Winkelmann RK, Oliver GF, Peters MS: Necrotizing fasciitis: A clinical, microbiological and histopathologic study of 14 patients. J Am Acad Dermatol 1989;20:774–781.
18.
Barker FG, Leppard BJ, Seal DV: Streptococcal necrotising fasciitis: Comparison between histological and clinical features. J Clin Pathol 1987;40:335–341.
19.
Lebre C, Girard-Pipau F, Roujeau JC, Revuz J, Saiag P, Chosidow O: Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 1996;132:842–843.
20.
Buchanan CS: Necrotizing fasciitis due to group A beta haemolytic streptococci. Arch Dermatol 1970;101:664–668.
21.
Ault MJ, Geiderman J, Sokolov R: Rapid identification of group A streptococcus as the cause of necrotizing fasciitis. Ann Emerg Med 1996;28:227–230.
22.
Rahmouni A, Chosidow O, Mathieu D, Gueorguieva E, Jazaerli N, Radier C, Faivre JM, Roujeau JC, Vasile N: MR imaging in acute infectious cellulitis. Radiology 1994;192:493–496.
23.
Schmid MR, Kossmann T, Duewell S: Differentiation of necrotizing faciitis and cellulitis using MR imaging. Am J Radiol 1998;170:615–620.
24.
Révélon G, Rahmouni A, Jazaerli N, Godeau B, Chosidow O, Authier J, Mathieu D, Roujeau JC, Vasile N: Acute swelling of the limbs: Magnetic resonance pictorial review of fascial and muscle signal changes. Eur J Radiol 1999;30:11–21.
25.
Leppard BJ, Seal DV: The value of bacteriology and serology in the diagnosis of necrotizing fasciitis. Br J Dermatol 1983;109:37–44.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.